Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BMY
stocks logo

BMY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
12.25B
-0.74%
1.647
-1.36%
10.53B
-5.96%
1.489
-17.29%
11.55B
-5.85%
1.599
+9.49%
Estimates Revision
The market is revising Upward the revenue expectations for Bristol-Myers Squibb Company (BMY) for FY2025, with the revenue forecasts being adjusted by 1.58% over the past three months. During the same period, the stock price has changed by 10.20%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.58%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.26%
In Past 3 Month
Stock Price
Go Up
up Image
+10.20%
In Past 3 Month
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 52.67 USD with a low forecast of 36.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 52.67 USD with a low forecast of 36.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
11 Hold
1 Sell
Moderate Buy
Current: 51.950
sliders
Low
36.00
Averages
52.67
High
68.00
Current: 51.950
sliders
Low
36.00
Averages
52.67
High
68.00
William Blair
Matthew Phipps
Market Perform
maintain
2025-12-03
New
Reason
William Blair
Matthew Phipps
Price Target
2025-12-03
New
maintain
Market Perform
Reason
William Blair analyst Matthew Phipps notes Bristol Myers today announced that its ADEPT-2 study evaluating Cobenfy in Alzheimer's disease psychosis will now read out by the end of 2026, versus prior timing for a readout by year-end 2025. The delay is due to the need for additional patient enrollment in the study given that irregularities were identified at several clinical trial sites, the analyst tells investors in a research note. Blair says that while a delay due to site irregularities typically raises concerns with investors, there is potentially a positive read-through in the Independent Data Monitoring Committee and Food and Drug Administration recommending continuation of the trial with more patients. This suggests positive trends are being observed, according to Blair. The firm thinks "any non-failure could be good news" given the selloff in Bristol Myers shares year-to-date. It has a Market Perform rating on the name. The stock in morning trading is up 5% to $50.76.
JPMorgan
analyst
Overweight
maintain
2025-12-03
New
Reason
JPMorgan
analyst
Price Target
2025-12-03
New
maintain
Overweight
Reason
After Bristol Myers announced that it is delaying the readout of the ADEPT-2 study of Cobenfy in Alzheimer's Psychosis as it adds more patients to the trial due to irregularities at some clinical trial sites, JPMorgan said the firm is "not completely surprised by this update" and sees it as an incremental positive. Expectations were low on ADEPT-2, the additional patient-adds enhances the chances of a successful study and this does not impact the timing of the FDA filing based on the remaining ADEPT study readouts, according to the analyst, who maintain an Overweight rating on the shares.
Leerink
David Risinger
Outperform
maintain
2025-12-03
New
Reason
Leerink
David Risinger
Price Target
2025-12-03
New
maintain
Outperform
Reason
Leerink analyst David Risinger notes that Bristol Myers announced that it will enroll additional patients in the ADEPT-2 study. The firm views it as positive news that the Data Monitoring Committee recommended enrolling additional patients in Cobenfy's ADEPT-2 trial in Alzheimer's disease psychosis patients. Recall that the company disclosed in early August that it was scrutinizing Cobenfy trial conduct, and Leerink and consensus feared the trial could fail. The firm keeps an Outperform rating on the shares.
Goldman Sachs
Neutral
maintain
$51 -> $57
2025-12-02
New
Reason
Goldman Sachs
Price Target
$51 -> $57
2025-12-02
New
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Bristol Myers to $57 from $51 and keeps a Neutral rating on the shares.
Citi
Neutral
maintain
$48 -> $45
2025-11-17
Reason
Citi
Price Target
$48 -> $45
2025-11-17
maintain
Neutral
Reason
Citi lowered the firm's price target on Bristol Myers to $45 from $48 and keeps a Neutral rating on the shares after the company announced the discontinuation of the Librexia acute coronary syndrome trial. Citi sees higher risk to the broader program following the news.
Scotiabank
initiated
$45
2025-11-12
Reason
Scotiabank
Price Target
$45
2025-11-12
initiated
Reason
Scotiabank initiated coverage of Bristol Myers with a Sector Perform rating and $45 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bristol-Myers Squibb Co (BMY.N) is 8.34, compared to its 5-year average forward P/E of 11.31. For a more detailed relative valuation and DCF analysis to assess Bristol-Myers Squibb Co 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
11.31
Current PE
8.34
Overvalued PE
24.90
Undervalued PE
-2.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.24
Undervalued EV/EBITDA
5.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.75
Current PS
0.00
Overvalued PS
3.28
Undervalued PS
2.22
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 15753.1% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 15753.1% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BMY News & Events

Events Timeline

(ET)
2025-12-04
20:30:00
Bristol Myers Squibb Receives FDA Approval for Breyanzi to Treat Relapsed Marginal Zone Lymphoma
select
2025-12-04
10:20:00
FDA Plans to Reduce Drug Approval Trials, Shares of Icon and Others Drop
select
2025-12-04
09:50:00
FDA Plans to Simplify Medical Product Approvals to One Clinical Study
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11:00 AMNASDAQ.COM
PinnedFDA Grants Approval for Bristol Myers Squibb's Breyanzi as the First CAR T Treatment for Relapsed/Refractory Marginal Zone Lymphoma

  • FDA Approval: Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) has been approved by the FDA for treating adult patients with relapsed or refractory marginal zone lymphoma after at least two prior therapies, marking it as the only CAR T cell therapy approved for five different cancer types.

  • Global Approvals: Breyanzi is also authorized in multiple countries, including Japan, the EU, Switzerland, Israel, the UK, and Canada, for various indications related to relapsed or refractory large B-cell lymphoma and follicular lymphoma, among others.

[object Object]
Preview
9.0
09:15 AMYahoo Finance
PinnedU.S. FDA Approves Bristol Myers Squibb's Breyanzi as the First CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

  • FDA Approval: The FDA has approved Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy, for adult patients with relapsed or refractory marginal zone lymphoma (MZL), making it the only CAR T therapy approved for five cancer types.

  • Efficacy and Safety: In the TRANSCEND FL study, Breyanzi demonstrated a 95.5% overall response rate in MZL patients, with a consistent safety profile, including manageable side effects like cytokine release syndrome and neurologic toxicities.

  • Treatment Process: Breyanzi is administered as a one-time infusion after a process that includes blood collection, CAR T cell creation, and lymphodepletion, with ongoing monitoring for side effects.

  • Commitment to Patients: Bristol Myers Squibb emphasizes its commitment to expanding access to innovative therapies like Breyanzi, supported by various patient resources and a digital service platform for treatment management.

[object Object]
Preview
9.0
12-04Benzinga
PinnedWhat’s Happening with Bristol-Myers Squibb Stock on Wednesday?

  • Bristol-Myers Squibb's ADEPT-2 Study Update: The company will enroll additional patients in the ADEPT-2 study after identifying irregularities at some trial sites, ensuring the integrity of the study.

  • FDA Consultation and Study Continuation: Following a review by the Data Monitoring Committee and consultation with the FDA, the study will continue with further patient enrollment to meet the original target population.

  • Trial Focus: ADEPT-2 is a Phase 3 trial assessing Cobenfy for treating psychosis associated with Alzheimer's disease dementia, with additional results expected by the end of 2026.

  • Stock Performance: Bristol-Myers shares rose 5.89% to $51.09 following the announcement, reflecting positive market response to the study's continuation.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bristol-Myers Squibb Co (BMY) stock price today?

The current price of BMY is 51.95 USD — it has increased 1.94 % in the last trading day.

arrow icon

What is Bristol-Myers Squibb Co (BMY)'s business?

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

arrow icon

What is the price predicton of BMY Stock?

Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 52.67 USD with a low forecast of 36.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bristol-Myers Squibb Co (BMY)'s revenue for the last quarter?

Bristol-Myers Squibb Co revenue for the last quarter amounts to 12.22B USD, increased 2.77 % YoY.

arrow icon

What is Bristol-Myers Squibb Co (BMY)'s earnings per share (EPS) for the last quarter?

Bristol-Myers Squibb Co. EPS for the last quarter amounts to 1.08 USD, increased 80.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bristol-Myers Squibb Co (BMY)'s fundamentals?

The market is revising Upward the revenue expectations for Bristol-Myers Squibb Company (BMY) for FY2025, with the revenue forecasts being adjusted by 1.58% over the past three months. During the same period, the stock price has changed by 10.20%.
arrow icon

How many employees does Bristol-Myers Squibb Co (BMY). have?

Bristol-Myers Squibb Co (BMY) has 34100 emplpoyees as of December 05 2025.

arrow icon

What is Bristol-Myers Squibb Co (BMY) market cap?

Today BMY has the market capitalization of 105.76B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free